Join Mineralys Therapeutics for a virtual KOL event featuring Luke J. Laffin, MD (Cleveland Clinic), James M. Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, MSc (Med), PhD (McGill University Health Centre), who will discuss the unmet medical need in uncontrolled and resistant hypertension (HTN) and the potential for lorundrostat, a highly selective aldosterone synthase inhibitor, to change the treatment paradigm.

The event will include an overview of Advance-HTN and Launch-HTN pivotal trial designs and results from Target-HTN, the Phase 2, proof-of-concept trial evaluating lorundrostat in uncontrolled or resistant hypertensive subjects. Company management will also provide an update on lorundrostat’s clinical development plans.

A live question and answer session will follow the formal presentation.